Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 6427 |
| PDBID: | 8SAK |
| Chains: | HL_B |
| Organism: | Middle East respiratory syndrome-related coronavirus, Macaca |
| Method: | EM |
| Resolution (Å): | 3.00 |
| Reference: | 10.1126/scitranslmed.adg5567 |
| Antibody | |
| Antibody: | JC57-11 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Middle East respiratory syndrome-like bat coronavirus BtCoV-422 spike glycoprotein |
| Antigen mutation: | Yes |
| Durg Target: | |
Sequence information
Antibody
Heavy Chain: H
Mutation: NULL
| >8SAK_H|Chain D[auth H]|JC57-11 Fab heavy chain|Macaca (9539) EVQLLESGPGVVRPSETLSLSCAVSGGSISDSYRWSWIRQPPGKGLEWVGYIFATGTTTNYNPSLKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCAREPFKYCSGGVCYAHKDNSLDVWGQGVLVTVSS |
Light Chain: L
Mutation: NULL
| >8SAK_L|Chain E[auth L]|JC57-11 Fab light chain|Macaca (9539) EIVMTQSPATLSLSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIHSASSRATGIPDRFSGSGSGTEFSLTISSLEAEDVGVYHCYQHSSGYTFGPGTKLDIK |
Antigen
Chain: B
Mutation: A885P/A1056P/V1057P
| >8SAK_B|Chain A, B, C|Spike glycoprotein|Middle East respiratory syndrome-related coronavirus (1335626) MRLSVCLLMFLLTPIKGDVDSGPPSSATSCKEADMRNSSSEFFNKQWPMPINASKADGIIYPTGKSYSNISLTLQGLFPKHGDLGEQYIYSVGHSDSNYDYLGKLFVSDYATKVVPFNNGFVVRIGAAANATGSVIISTVQKTIKKIYPAFMLGSSVGNFSNGVSGRYFNHTLLLLPDGCGTRLWALYCVIEPRNGSYCPGNSNYNTFAVFDTPHTDCTSAGYNTNATLNSFKEYFDLQNCSFIYSFNITEDENAEWFGITQNTQGVHLYSSRKGDLYGSNMFLFATLPVYDGIKYYTVIPRSIRSKYSERQAWAAFYIYSLHKLTYLLDFSVDGYIRRAVDCGHDDLSQLYCSYESFDVGSGVYSVSSFEVHSRGQFIEQPNSVECDFTKLLSGTPPQVYNFNRLVFTNCNYNLTKLLSLFMVNEFSCDGISPDAIARGCYSSLTVDYFAYPLSMKSYMQPGSAGVISQYNYKQSFANPTCRIFATAPANLTITKPSSYSFISKCSRLTGDNSHIETPIVINPGEYSICKNFAPNGFSQDGDYFTRQLSQLEGGGILVGVGSVTPMTDTLQMGFIISVQYGTDTNSVCPMMDLGNSTTITDKLGVCVEYNLYGVSGRGVFINCTAVGVKQQRFVYDGFDNLIGYYSDDGNYYCVRPCVSVPLSVVYDKTTNSHATIFGSVACEHITTMLHQFSRTTQASLRMRDVSNSGPLQTAVGCVIGLVNSSMVVDNCQLPLGQSLCAVPSTTRSSSQLQLATINYTQPQLLSPLNSSGFVVQVPTNFSFGITQEYIQTTIQKVTVDCKQYVCNGFQKCEQLLREYGQFCAKINQALHGANLMQDESVANLFSDIKTHKSQPLNAGLNGDFNLTLLQVPQVSTSQYSHRSPIEDLLFNKVTIADPGYMQGYDDCMKQGPPSARDLICAQYVAGYKVLPPLYDPNMEGAYTSSLLGSIAGAGWTAGLSSFAAIPFAQSIFYRMNGIGITQQVLSENQKLIANKFNQALGAMQTGFTTTNLAFSKVQDAVNANAQALSKLASELSNTFGAISSSISDILKRLDPPEQEAQIDRLINGRLTSLNAFVAQQLVRSETAARSAQLASDKVNECVKSQSKRNGFCGSGTHIVSFVINAPNGFYFFHVGYVPTNHVNVTAAYGLCNTDTPPRCIAPIDGYFVLNNTTTRDVVDQWYYTGSSFFNPEPITMANARYVSQDVKFENLTNQLPPPLLNNQTDLDFKEELEEFFKNVSSQGPNFQEISKINTTLLDLSTEMKVLNEVVKQLNESYIDLKELGNYSY |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition H: TYR33 THR53 GLY54 THR55 THR56 LYS71 THR73 PHE97 TYR99 L: ASN32 B: LYS505 LEU509 ASN513 SER514 HIS515 GLU517 PHE533 SER539 GLN540 ASP541 GLY542 ASP543 TYR544 PHE545 THR546 ARG547 GLN548 ILE557 VAL559 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 6 Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 6 Å from any atom.
Interacting residues (Atom distance based)
